Value of interleukin- 28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.

Autor: Chen, Ming‐Yao, Liu, Chen‐Hua, Chen, Ting‐Chih, Su, Tung‐Hung, Chen, Pei‐Jer, Chen, Ding‐Shinn, Kao, Jia‐Horng, Liu, Chun‐Jen
Předmět:
Zdroj: Journal of Gastroenterology & Hepatology; Jan2014, Vol. 29 Issue 1, p102-109, 8p
Abstrakt: Background and Aim Chronic hepatitis C ( CHC) infection is a leading cause of cirrhosis and hepatocellular carcinoma worldwide. Pegylated interferon ( PEG-IFN) plus ribavirin ( RBV) combination therapy remains the standard of care for CHC genotype 1 in many Asian countries, and single nucleotide polymorphism or genotype of the interleukin- 28B ( IL28B) gene is associated with the development of sustained virologic response ( SVR). The predictive value of IL28B genotype for retreatment outcomes of patients with CHC was only partly clarified and deserves further investigation. Methods A total of 75 CHC genotype 1 Taiwanese patients who relapsed after 24-week PEG-IFN/ RBV combination therapy and received retreatment with a 48-week PEG-IFN/ RBV therapy were consecutively enrolled since November 2009. The associations among IL28B rs8099917 genotype, virologic kinetics, and treatment outcomes were evaluated. Results Rapid virologic response ( RVR) at week 4, end-of-treatment virologic response ( EOT-VR) and SVR was 37%, 73%, and 52%, respectively. Relapse rate was 29%. None of patients had rs8099917 GG genotype. Patients with TT genotype ( n = 54, 72%) had higher rates of RVR (50% vs 5%, P = 0.0002), end-of-treatment virologic response (85% vs 43%, P = 0.0001), and SVR (67% vs 14%, P = 0.0001) than those with GT genotype ( n = 21, 28%). Combination of IL28B TT genotype and achieving RVR had 85% positive and 90% negative predictive values of SVR. Conclusions About half of the Taiwanese CHC relapsers to a previous 24-week combination therapy achieve SVR after retreatment for 48 weeks. IL28B genotype influences on-treatment viral kinetics and SVR rate in these retreated patients. Baseline IL28B genotype and RVR can serve as early predictors for treatment success. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index